Brief Communication Published: 05 May 2005 The expression of legumain, an asparaginyl endopeptidase that controls antigen processing, is reduced in endotoxin-tolerant monocytes K Wolk, G Grütz, K ...

Legumain (LGMN), or asparaginyl endopeptidase, is a newly identified lysosomal cysteine protease. It was recently found to be over-expressed in tumour microenvironment , an enclosed environment ...

Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described haloacethydrazide compounds acting as legumain (asparaginyl endopeptidase; LGMN; AEP) inhibitors reported to be ...

The proteins produced by legumain and Bag1 have been modified in sharks to the extent that they actually protect the animals from the disease instead of exposing them to it.

VIP924 consists of an anti-CXCR5 humanized monoclonal antibody with a novel linker containing a unique peptide sequence specifically cleaved by legumain—a tumor-associated lysosomal protease ...

Target Legumain could be the next promising strategy for development of Tumor- Specific Treatement. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to ...

Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described haloacethydrazide compounds acting as legumain (asparaginyl endopeptidase; LGMN; AEP) inhibitors reported to be ...

VIP924, a first-in-class CXCR5-ADC showed significant activity in patient-derived (PDX) lymphoma mouse models PALO ALTO, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq ...